跳至主要内容
临床试验/NCT00086138
NCT00086138已完成2 期

Depression in Alzheimer's Disease (DIADS-2)

Johns Hopkins University5 个研究点 分布在 1 个国家目标入组 131 人开始时间: 2004年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
131
试验地点
5
主要终点
Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)

研究概览

简要总结

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

详细描述

Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks. Visits include neuropsychological testing. Caregivers are asked to are the patient on a Daily Affect Diary for 6 weeks during the study period. Telephone followup is done at weeks 36 and 48. Both groups receive caregiver support/education.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

Participants will receive sertraline at a target dose of 100mg daily.

干预措施: Sertraline (Zoloft) (Drug)

2

Placebo Comparator

Participants will receive placebo matched to sertraline

干预措施: Placebo (Drug)

结局指标

主要结局

Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)

时间窗: Measured at Week 12

At each study visit, based on patient examination and caregiver interview, clinicians rated overall impression of clinical change from baseline using the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change index (mADCS-CGIC), which in addition to the original scale incorporates a global rating of mood and associated symptoms of depression. The mADCS-CGIC uses a seven-point Likert scale, with scores ranging from 1 ("much better") to 7 ("much worse"), with a score of 4 being "no change".

次要结局

  • Remission According to Cornell Scale for Depression in Dementia Scale(Measured at Weeks 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Constantine G. Lyketsos

Chairman, Bayview Psychiatry

Johns Hopkins University

研究点 (5)

Loading locations...

相似试验